marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Protagonist Therapeutics Balance Sheet 2011-2024 | PTGX
Annual Balance Sheet Protagonist Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-122 M | -118 M | -111 M | 76.8 M | -82.2 M | -106 M | -21.1 M | -4.06 M | -9.32 M | - | - | - | |
Long Term Debt |
- | 1.14 M | 3.66 M | 4.5 M | 9.79 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.14 M | 2.52 M | 2.2 M | 1.46 M | 1.26 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 39.5 M | 799 K | 547 K | - | 2.12 M | 1.02 M | - | - | - |
Total Current Liabilities |
21.3 M | 31.2 M | 44 M | 40.2 M | 35.4 M | 26.2 M | 42.6 M | 6.44 M | - | - | - | - | - |
Total Liabilities |
21.3 M | 32.3 M | 47.7 M | 44.9 M | 75 M | 27 M | 43.1 M | 6.44 M | 5.25 M | 2.37 M | - | - | - |
Deferred Revenue |
3 K | 69 K | 899 K | 17.2 M | 19 M | 9.28 M | 31.8 M | - | - | - | - | - | - |
Retained Earnings |
-616 M | -537 M | -409 M | -284 M | -218 M | -140 M | -102 M | -64.6 M | -27.4 M | -12.6 M | - | - | - |
Total Assets |
358 M | 248 M | 348 M | 324 M | 155 M | 139 M | 164 M | 94 M | 14.8 M | 10.3 M | - | - | - |
Cash and Cash Equivalents |
187 M | 126 M | 124 M | 117 M | 33 M | 82.2 M | 106 M | 21.1 M | 4.06 M | - | - | - | - |
Book Value |
337 M | 216 M | 300 M | 280 M | 80 M | 113 M | 121 M | 87.6 M | 9.6 M | 7.96 M | - | - | - |
Total Shareholders Equity |
337 M | 216 M | 300 M | 280 M | 80 M | 113 M | 121 M | 87.6 M | -27.4 M | -12.6 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Protagonist Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
10.9 M | 11 M | - | - | - | - | 462 K | 1.14 M | 1.8 M | - | 3.06 M | 3.66 M | 4.24 M | 3.69 M | 4.1 M | 4.5 M | 4.5 M | 4.5 M | 9.83 M | 9.79 M | 9.79 M | 9.79 M | 9.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
71.9 M | 73.3 M | 68.8 M | 21.3 M | 27.9 M | 26.4 M | 23.7 M | 32.3 M | 38.6 M | - | 46.5 M | 47.7 M | 43.5 M | 46.8 M | 38.7 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 75 M | 75 M | 75 M | 75 M | 27 M | 27 M | 27 M | 27 M | 43.1 M | 43.1 M | 43.1 M | 43.1 M | 6.44 M | 6.44 M | 6.44 M | - | 5.25 M | 5.25 M | 5.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 3 K | 3 K | 3 K | - | - | 69 K | 32 K | - | 768 K | 1.6 M | 2.24 M | 2.01 M | 5.77 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 8.22 M | 8.22 M | 8.22 M | 8.22 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-472 M | -439 M | -408 M | -616 M | -643 M | -609 M | -570 M | -537 M | -503 M | - | -430 M | -409 M | -372 M | -339 M | -308 M | -284 M | -284 M | -284 M | -284 M | -218 M | -218 M | -218 M | -218 M | -140 M | -140 M | -140 M | -140 M | -102 M | -102 M | -102 M | -102 M | -64.6 M | -64.6 M | -64.6 M | -64.6 M | -27.4 M | -27.4 M | -27.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
604 M | 615 M | 629 M | 358 M | 330 M | 320 M | 240 M | 248 M | 282 M | - | 348 M | 348 M | 373 M | 404 M | 298 M | 324 M | 324 M | 324 M | 324 M | 155 M | 155 M | 155 M | 155 M | 139 M | 139 M | 139 M | 139 M | 164 M | 164 M | 164 M | 164 M | 94 M | 94 M | 94 M | 94 M | 14.8 M | 14.8 M | 14.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
131 M | 356 M | 173 M | 187 M | 231 M | 235 M | 128 M | 126 M | 153 M | 120 M | 98.5 M | 124 M | 121 M | 192 M | 83 M | 117 M | 117 M | 117 M | 117 M | 33 M | 33 M | 33 M | 33 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 106 M | 106 M | 106 M | 106 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 4.06 M | 4.06 M | 4.06 M | - | 9.32 M | - | - | - | 8.46 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
532 M | 541 M | 560 M | 337 M | 302 M | 294 M | 216 M | 216 M | 244 M | - | 302 M | 300 M | 330 M | 357 M | 259 M | 280 M | 280 M | 280 M | 280 M | 80 M | 80 M | 80 M | 80 M | 113 M | 113 M | 113 M | 113 M | 121 M | 121 M | 121 M | 121 M | 87.6 M | 87.6 M | 87.6 M | 94 M | 9.6 M | 9.6 M | 9.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
532 M | 541 M | 560 M | 337 M | 302 M | 294 M | 216 M | 216 M | 244 M | 268 M | 302 M | 300 M | 330 M | 357 M | 259 M | 280 M | 280 M | 280 M | 280 M | 80 M | 80 M | 80 M | 80 M | 113 M | 113 M | 113 M | 113 M | 121 M | 121 M | 121 M | 121 M | 87.6 M | 87.6 M | 87.6 M | 87.6 M | -27.4 M | -27.4 M | -27.4 M | - | -12.6 M | - | - | - | -1.39 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency